Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Source comparison

PT141: Comparison Table

PT141 operates through a distinct mechanism compared to other arousal-modulating compounds. The table below compares PT141 with PDE5 inhibitors and dopamine agonists across key research parameters. | Compound | Mechanism of Action | Primary Receptor Target | O

This comparison does not assign a generated winner or score.

  • PT141 operates through a distinct mechanism compared to other arousal-modulating compounds. The table below compares PT141 with PDE5 inhibitors and dopamine agonists across key research parameters.
  • | Compound | Mechanism of Action | Primary Receptor Target | Onset Time | Half-Life | Vascular Dependence | Most Common Adverse Event ||—|—|—|—|—|—|| PT141 (Bremelanotide) | Melanocortin receptor agonist | MC3/MC4 receptors in hypothalamus | 30–60 minutes | 2.7 hours | No. Acts centrally, independent of vascular function | Nausea (18–25% at 1.75mg dose) || Sildenafil (Viagra) | PDE5 inhibitor | Phosphodiesterase-5 enzyme in vascular smooth muscle | 30–60 minutes | 4 hours | Yes. Requires intact nitric oxide/cGMP pathway | Headache (16%), flushing (10%) || Tadalafil (Cialis) | PDE5 inhibitor | Phosphodiesterase-5 enzyme in vascular smooth muscle | 30–120 minutes | 17.5 hours | Yes. Requires intact vascular endothelium | Headache (15%), back pain (6%) || Cabergoline | Dopamine D2 agonist | D2 dopamine receptors in anterior pituitary and CNS | 2–3 hours (chronic dosing required) | 63–69 hours | No. Modulates prolactin and central dopamine tone | Orthostatic hypotension (15%) |